Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes

Hepatology

Volumn 54, Issue 4, 2011, Pages 1149-1156

  Mazumdar, Budhaditya ^a   Banerjee, Arup ^a   Meyer, Keith ^a   Ray, Ranjit ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; APOLIPOPROTEIN B; APOLIPOPROTEIN E; GLYCOPROTEIN E1; GLYCOPROTEIN E2; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN; SYNTHETIC PEPTIDE; THROMBOCYTE FACTOR 4;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; VESICULAR STOMATITIS VIRUS; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

ANIMALS; APOLIPOPROTEINS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HEPATOCYTES; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; PLATELET FACTOR 4; RABBITS; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 79961216296     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24523     Document Type: Article

References (37)

1. Lagging LM, Meyer K, Owens RJ, Ray R. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus infectivity. J Virol 1998; 72: 3539-3546.
2. Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, Conley AJ, et al. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 2002; 76: 2150-2158.
3. Meyer K, Beyene A, Bowlin TL, Basu A, Ray R. Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer. J Virol 2004; 78: 12838-12847.
4. Basu A, Beyene A, Meyer K, Ray R. The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system. J Virol 2004; 78: 4478-4486.
5. Basu A, Kanda T, Beyene A, Saito K, Meyer K, Ray R. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 2007; 81: 3933-3941.
6. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
7. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100: 7271-7276.
8. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 41003-41012.
9. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805.
10. Drummer HE, Poumbourious P. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. J Biol Chem 2004; 279: 30066-30072.
11. Garry RF, Dash S. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 2003; 307: 255-265.
12. Lavillette D, Pécheur EI, Donot P, Fresquet J, Molle J, Corbau R, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 2007; 81: 8752-8765.
13. Takikawa S, Ishii K, Aizaki H, Suzuki T, Asakura H, Matsuura Y, et al. Cell fusion activity of hepatitis C virus envelope proteins. J Virol 2000; 74: 5066-5074.
14. Albecka A, Monserret R, Krey T, Tarr AW, Diesis E, Ball JK, et al. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol 2011; 85: 1777-1792.
15. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol 1993; 182: 329-334.
16. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-6928.
17. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82: 2120-2129.
18. Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramiere C, Bartenschlager R, et al. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One 2009; 4: e4233.
19. Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 2009; 83: 12680-12691.
20. Owen DM, Huang H, Ye J, Gale M., Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108.
21. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766-12771.
22. Molina S, Castet V, Fournier-Worth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46: 411-419.
23. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57: 223-229.
24. Dorfman SE, Lichtenstein AH. Dietary fatty acids differentially modulate messenger RNA abundance of low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and microsomal triglyceride transfer protein in Golden-Syrian hamsters. Metab Clin Exp 2006; 55: 635-641.
25. Kanda T, Basu A, Steele R, Wakita T, Ryerse JS, Ray R, et al. Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol 2006; 80: 4633-4639.
26. Ray R, Khanna A, Lagging M, Meyer K, Choo QL, Ralston R, et al. Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. J Virol 1994; 68: 4420-4426.
27. Lorent E, Bierau H, Engelborghs Y, Verheyden G, Bosman F. Structural characteristics of the hepatitis C envelope glycoprotein E1 derived from a mammalian and a yeast expression system. Vaccine 2008; 26: 399-410.
28. Ciccaglione AR, Costantino A, Marcantonio C, Equestre M, Geraci A, Rapicetta M. Mutagenesis of hepatitis C virus E1 protein affects its membrane-permeabilizing activity. J Gen Virol 2001; 82: 2243-2250.
29. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 2008; 105: 1820-1825.
30. Sachais BS, Kuo A, Nassar T, Morgan J, Kariko K, Williams KJ, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 3613-3622.
31. Meyer K, Basu A, Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 2000; 276: 214-226.
32. Maillard P, Huby T, Andréo U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J 2006; 20: 735-737.
33. Hatters DM, Peters-Libeu CA, Weisgraber K. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31: 445-454.
34. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42: 1346-1367.
35. Denis N, Palmer-Smith H, Elisma F, Busuttil A, Wright TG, Bou Khalil M, et al. Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells. J Proteome Res 2011; 10: 2011-2026.
36. Zaldivar MM, Pauels K, von Hundelshausen P, Berres ML, Schmitz P, Bornemann J, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. HEPATOLOGY 2010; 51: 1345-1353.
37. Dominguez M, Miquel R, Colmenero J, Moreno M, García-Pagán JC, Bosch J, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009; 136: 1639-1650.